AstraZeneca Group (AZN)
AstraZeneca Group Gross Profit Margin: 81.29%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AZN Gross Profit Margin Rankings
| Overall | 86th percentile | 523 of 3914 |
| Sector | 83rd percentile | 60 of 368 in Healthcare |
| Industry | 94th percentile | 1 of 17 in Drug Manufacturers - Major |
AZN Gross Profit Margin Range, Past 5 Years
| Minimum | 74.22% | Dec 2008 |
| Maximum | 84.60% | Sep 2009 |
| Average | 80.90% |
About Gross Profit Margin
Gross profit margin is the difference between sales and the cost of goods sold divided by revenue. It expresses the relationship between gross profit (sales - cost of goods sold) and sales revenue. More specifically, gross profit margin represents the percentage of each dollar of a company's revenue that is available to cover fixed costs after paying for the goods or services that were sold.
If a company produces widgets and earns $32 million in sales but pays $24 million for the items sold, then the company's gross profit margin would be ($32m - $24m)/$32m = %25.
Learn More
You may also be interested in these AZN related companies
AZN News
$AZN stop at 40 on 1/3. Have owned a ton of it since early '10. Cost basis ~46 (not inc. divies)
about 4 days ago by WallStreetBean
about 4 days ago by WallStreetBean
RT @SeemaCnbc Cancer data expected to move big pharma $JNJ $PFE $AZN
about 10 days ago by StockTwits
about 10 days ago by StockTwits
$AZN “no longer operating in isolation as a pharmaceutical organization.” http://stks.co/3nwQ
about 14 days ago by WallStreetBean
about 14 days ago by WallStreetBean
AstraZeneca (AZN) Says SYMBICORT Shows Similar Safety Profile to Budesonide in Certain Asthma Patient Groups
May 10, 9:02AM Street Insider
May 10, 9:02AM Street Insider
UPDATE - Canaccord Genuity Downgraded Ardea Biosciences (RDEA) To 'Hold'; Q1 Is Non-Event In Light Of Acquisition By AZN
May 08, 9:14AM Street Insider
May 08, 9:14AM Street Insider
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 20 days ago by abubnic
about 20 days ago by abubnic
$AMRN U.K.'s second-biggest drugmaker, pharmaceutical giant $AZN, based in London is sniffing around Ireland's small biotech $AMRN
about 23 days ago by JasonMilano8
about 23 days ago by JasonMilano8
News related to $AZN, currently +0.3% since open: 'Impax Labs falls on weak sales, new FDA warning' http://stks.co/3bhx
about 26 days ago by TradeBot
about 26 days ago by TradeBot
what kinda drug is that? RT @JNapodano $AZN reported $16M in sales of Vimovo - not great, but still higher than consensus. $POZN.
about 27 days ago by WallStreetBean
about 27 days ago by WallStreetBean
Morning News: April 26, 2012 | via @EddyElfenbein http://stks.co/3Wht $FED $DB $NDX $AAPL $CAT $AZN
about 31 days ago by STNet
about 31 days ago by STNet
$AZN trouble in paradise: AstraZeneca CEO to step down as Q1 profit plunges http://stks.co/3WZ3 (holding)
about 31 days ago by WallStreetBean
about 31 days ago by WallStreetBean
News related to $AZN: 'AstraZeneca CEO to step down as Q1 profit plunges' http://stks.co/3WIC
about 32 days ago by TradeBot
about 32 days ago by TradeBot
@taketheplunge $AMRN $AZN has been linked to every biotech on the market in the last 3 months. $AZN could buy...
about 32 days ago by jackofalltrade
about 32 days ago by jackofalltrade
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 41.23 | +0.05 | +0.12% | 53.28B |
| AZK | 4.72 | +0.11 | +2.39% | 769.97M |
| AZC | 1.63 | +0.13 | +8.67% | 235.05M |
| AYR | 11.60 | +0.37 | +3.29% | 839.61M |
| BCRX | 3.26 | +0.00 | +0.00% | 150.09M |
| BCR | 99.90 | -0.09 | -0.09% | 8.473B |
| BCPC | 30.31 | -0.25 | -0.82% | 885.36M |
| BCOM | 4.20 | +0.01 | +0.24% | 125.54M |
| BCO | 23.23 | -0.32 | -1.36% | 1.089B |
| BCH | 84.05 | +0.83 | +1.00% | 12.18B |
